Conditions: Peripheral Neuropathy
Keywords: chemotherapy peripheral neuropathy paclitaxel breast cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 9
Healthy volunteers: no

Brief summary:
This study is being done because peripheral neuropathy, a condition that interrupts sensation in your limbs, is a common side effect of paclitaxel. There is some evidence that alpha lipoic acid (ALA), an antioxidant compound, protects neurons after exposure to paclitaxel. The purpose of this study is to assess the safety and tolerability of ALA and to find the best dose of ALA in patients that receive chemotherapy.

Detailed description:

Arms:
arm 1: Oral administration three times daily (morning, mid-day, night)

Interventions: intervention 1: Alpha lipoic acid
Intervention descriptions: intervention 1: The baseline dose is 100 mg three times daily for four months. Dose escalation will occur until a maximum tolerated dose is found.

Protocol document: